
|Videos|June 10, 2021
What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease
Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































